Pramipexole for the treatment of early Parkinson’s disease

References

• Poewe W. The natural history of Parkinson’s disease. J. Neurol.253(Suppl. 7), VII2–VII6 (2006).
   PubMedGoogle Scholar
• Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol.12(Suppl. 1), 1–27 (2005).
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N. Engl. J Med.339, 1044–1053 (1998).
   PubMed Web of Science ®Google Scholar
• Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov. Disord.18, 19–31 (2003).
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat. Disord.4, 59–60 (1998).
   PubMedGoogle Scholar
• Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord.19, 997–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology40, 340–345 (1990).
   PubMed Web of Science ®Google Scholar
• Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson’s disease therapy. Ann. Neurol.53(Suppl. 3), S3–S12 (2003).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology72, S1–S136 (2009).
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin. Pharmacokinet.41, 261–309 (2002).
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol.6, 826–829 (2007).
   PubMed Web of Science ®Google Scholar
• Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinson’s disease. CNS Drugs24, 829–841 (2010).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Treatment options in the modern management of Parkinson disease. Arch. Neurol.64, 1083–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Aminoff MJ. Treatment should not be initiated too soon in Parkinson’s disease. Ann. Neurol.59, 562–564 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann. Neurol.59, 559–562 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson’s disease. Ann. Neurol.64(Suppl. 2), S47–S55 (2008).
   PubMedGoogle Scholar
• Bennett JP Jr, Piercey MF. Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease. J. Neurol. Sci.163, 25–31 (1999).
   PubMed Web of Science ®Google Scholar
• Piercey MF, Hyslop DK, Hoffmann WE. Excitation of type II caudate neurons by systemic administration of dopamine agonists. Brain Res.706, 249–258 (1996).
   PubMed Web of Science ®Google Scholar
• Hubble JP. Pre-clinical studies of pramipexole: clinical relevance. Eur. J. Neurol.7(Suppl. 1), 15–20 (2000).
   PubMed Web of Science ®Google Scholar
• Li C, Guo Y, Xie W, Li X, Janokovic J, Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson’s disease. Neurochem. Res.35, 1546–1556 (2010).
   PubMed Web of Science ®Google Scholar
• Patterson TA, Li M, Hotchkiss CE et al. Toxicity assessment of pramipexole in juvenile rhesus monkeys. Toxicology276, 164–171 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson PS, Madden GJ, Brewer AT, Pinkston JW, Fowler SC. Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats. Psychopharmacology (Berl.)213, 11–18 (2010).
   PubMed Web of Science ®Google Scholar
• Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch. Neurol.63, 1343–1344 (2006).
   PubMedGoogle Scholar
• Jenner P, Könen-Bergman M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin. Therap.31, 2698–2711 (2009).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord.20, 523–539 (2005).
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton RL, and members of the UPDRS committee. Unified Parkinson’s disease rating scale. In: Recent Developments in Parkinson’s Disease. Mardsen CD, Golstein M, Calne DB (Eds). McMillan, NY, USA, 153–163 (1987).
   Google Scholar
• Hubble JP, Koller WC, Cutler NR et al. Pramipexole in patients with early Parkinson’s disease. Clin. Neuropharmacol.18, 338–347 (1995).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology49, 724–728 (1997).
   PubMed Web of Science ®Google Scholar
• Parkinson ’s Disease Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA284, 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61, 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson ’s Disease Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch. Neurol.66, 563–570 (2009).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Schapira AH, Rascol O et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov. Disord.25, 2542–2549 (2010).
   PubMed Web of Science ®Google Scholar
• Parkinson ’s Disease Study Group. Twice-daily, low-dose pramipexole in early Parkinson’s disease: a randomized, placebo-controlled trial. Mov. Disord.26(1), 37–44 (2011).
   PubMed Web of Science ®Google Scholar
• Rascol O, Barone P, Hauser RA et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov. Disord.25, 2326–2332 (2010).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342, 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov. Disord.20, 342–344 (2005).
   PubMed Web of Science ®Google Scholar
• Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov. Disord.22, 1317–1319 (2007).
   PubMed Web of Science ®Google Scholar
• Winogrodzka A, Booij J, Wolters EC. Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson’s disease. Parkinsonism Relat. Disord.11, 475–484 (2005).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287, 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology56, 1559–1564 (2001).
   PubMed Web of Science ®Google Scholar
• Sossi V, Dinelle K, Schulzer M, Mak E, Doudet DJ, de la Fuente-Fernández R. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur. J. Nucl. Med. Mol. Imaging37, 2364–2370 (2010).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Albrecht S, Barone P et al. Inmediate vs delayed-start pramipexole in early Parkinson’s disease: the PROUD study. Parkinsonism Relat. Disord.15S2, S29–S199 (2009).
   Google Scholar
• Schapira AH, Albrecht S, Barone P et al. Rationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD study. Mov. Disord.25, 1627–1632 (2010).
   PubMed Web of Science ®Google Scholar
• Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord.23, 183–189 (2008).
   PubMed Web of Science ®Google Scholar
• Pankratz N, Marder KS, Halter CA et al. Clinical correlates of depressive symptoms in familial Parkinson’s disease. Mov. Disord.23, 2216–2223 (2008).
   PubMed Web of Science ®Google Scholar
• Schrag A. Quality of life and depression in Parkinson’s disease. J. Neurol. Sci.248, 151–157 (2006).
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol.9, 573–580 (2010).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Kurtis MM. Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. Parkinsonism Relat. Disord.15(Suppl. 4), S58–S64 (2009).
   Google Scholar
• Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs24, 941–968 (2010).
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martinez-Bengoechea MJ, Garcia-Monco JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson’s disease. Am. J. Health Syst. Pharm.65, 414–419 (2008).
   PubMed Web of Science ®Google Scholar
• Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov. Disord.22, 1543–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Biglan KM, Holloway RG Jr, McDermott MP, Richard IH. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology69, 187–195 (2007).
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv. Neurol.65, 115–138 (1995).
   PubMedGoogle Scholar
• The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. The French Clozapine Parkinson Study Group. Lancet353, 2041–2042 (1999).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763 (1999).
   PubMed Web of Science ®Google Scholar
• Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf.32, 475–488 (2009).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol.67, 589–595 (2010).
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL. Adverse drug reactions to dopamine agonists: a comparative study in the french pharmacovigilance database. Mov. Disord.25(12), 1876–1880 (2010).
   PubMed Web of Science ®Google Scholar
• Rossi M, Gerschcovich ER, de Achaval D et al. Decision-making in Parkinson’s disease patients with and without pathological gambling. Eur. J. Neurol.17, 97–102 (2009).
   PubMedGoogle Scholar
• Khan W, Rana AQ. Dopamine agonist induced compulsive eating behaviour in a Parkinson’s disease patient. Pharm. World Sci.32, 114–116 (2010).
   PubMedGoogle Scholar
• Odiyoor M, Kobylecki C, Hackett RJ, Silverdale MA, Kellett MW. Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinson’s disease. Mov. Disord.24, 2434–2435 (2009).
   PubMed Web of Science ®Google Scholar
• Bienfait KL, Menza M, Mark MH, Dobkin RD. Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. J. Clin. Neurosci.17, 539–540 (2010).
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Verde F et al. Exercise dependence induced by pramipexole in Parkinson’s disease – a case report. Mov. Disord.25, 2893–2894 (2010).
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Homann CN, Suppan K, Wenzel K, Ivanic G, Kriechbaum N, Ott E. Sleep attacks with apomorphine. Wien. Klin. Wochenschr.114, 430–431 (2002).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet355, 1332–1333 (2000).
   PubMed Web of Science ®Google Scholar
• Tan EK. Piribedil-induced sleep attacks in Parkinson’s disease. Fundam. Clin. Pharmacol.17, 117–119 (2003).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson’s disease treatment. Lancet355, 1333–1334 (2000).
   PubMed Web of Science ®Google Scholar
• Ryan M, Slevin JT, Wells A. Non-ergot dopamine agonist-induced sleep attacks. Pharmacotherapy20, 724–726 (2000).
   PubMed Web of Science ®Google Scholar
• Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomised controlled trials. Drug Saf.24, 863–868 (2001).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Thalamas C et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology58, 460–462 (2002).
   PubMed Web of Science ®Google Scholar
• Micallef J, Rey M, Eusebio A et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of l-dopa, bromocriptine and pramipexole in healthy subjects. Br. J. Clin. Pharmacol.67, 333–340 (2009).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov. Disord.15, 1269–1271 (2000).
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov. Disord.18, 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Quilici S, Abrams KR, Nicolas A et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med.9, 715–726 (2008).
   PubMed Web of Science ®Google Scholar
• Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol.64, 1089–1096 (2007).
   PubMedGoogle Scholar